Suicide of Abbott rep in India raises questions about sales tactics

Pills and vitamins

Reports that a sales representative at Abbott Laboratories($ABT)  in India cited work performance demands in a suicide note have reverberated among colleagues, the Economic Times said, with calls for the drugmaker to take action.

The newspaper said the death of Ashish Awasthi, 35, was possibly a suicide. A note that blamed pressure to meet sales targets was found, sparking colleagues in the central Indian city of Indore to demand the company compensate his family and work on designing better work conditions.

Abbott, which is the country's second largest drugmaker by market share through unit Abbott India, told the newspaper that its marketing practices in India adhere to local laws and industry codes and regular training is part of its efforts.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

GlaxoSmithKline ($GSK) said earlier this month that India was the next stop on its global program to revamp marketing and sales away from hard targets as part of changes from the wake of a $489 million fine it paid for bribing doctors and hospitals in China to buy its drugs.

Last year, other firms said they also plan sales and marketing changes in India by hiring younger graduates to sell directly to specialist physicians as newer drugs phase out an older model based on targets.

In the case of Abbott, the union in the country that represents sales reps has written to top executives in India and in the U.S. on what they termed, "continuous pressure, mental harassment on sales promotion employees and punitive action against field-level staff," according to the newspaper.

- here's the story from the Economic Times

Related Articles:
Abbott CEO White 'cautious' on China pediatric nutrition sales in Q2 call
India is next stop for GSK sales and marketing overhaul
Indian drug companies eye fresh management grads as sales reps


Suggested Articles

Contradicting analysts' observations, Novartis CEO dubbed Zolgensma “one of the most successful launches from an access standpoint in rare diseases.”

Leading Indian drugmakers Sun Pharma, Cipla, Aurobindo and Dr. Reddy's are all trying to expand their presences in China.

New Gilead CEO Daniel O’Day has already replaced some key leaders at the company, but he’s not stopping there with the executive overhaul.